ERBB2 and breast benign neoplasm: This implies that breast tumor cells with increased malignancy properties, in our case, stromal cells from phyllodes benign breast tumor and epithelial cells from luminal B and HER2+ breast cancer subtypes changed the FAK Tyr residue phosphorylation from FAKY397 to FAKY925.